Finding better ways to treat brain blood vessel constriction after a stroke.
Development of biomarkers to optimize intrathecal nicardipine treatment for cerebral vasospasm and delayed cerebral ischemia after subarachnoid hemorrhage
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-10908464
This study is looking at how a medication called nicardipine can help people who have had a type of stroke called a subarachnoid hemorrhage by improving blood flow in the brain and reducing the risk of serious complications, and they're also trying to find ways to predict who will benefit the most from this treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-10908464 on ClinicalTrials.gov |
What this research studies
This research focuses on improving treatment for patients who experience cerebral vasospasm, a dangerous condition that can occur after a subarachnoid hemorrhage (a type of stroke). The team at Emory University is investigating the use of intrathecal nicardipine, a medication that helps widen blood vessels in the brain, to reduce the risk of delayed cerebral ischemia, which can severely affect recovery. They aim to develop biomarkers that can predict how well patients will respond to this treatment, using advanced non-invasive techniques to measure blood flow in the brain. By identifying the right patients for this therapy, the research hopes to enhance treatment outcomes and overall patient survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have experienced a subarachnoid hemorrhage and are at risk for cerebral vasospasm.
Not a fit: Patients who have not experienced a subarachnoid hemorrhage or those with other unrelated neurological conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients recovering from subarachnoid hemorrhage, potentially improving survival rates and long-term recovery.
How similar studies have performed: Previous studies have shown promising results with the use of intrathecal nicardipine in similar patient populations, indicating potential for success in this research.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SADAN, OFER — EMORY UNIVERSITY
- Study coordinator: SADAN, OFER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired brain injury